Clinical trial NCT05983328: Phase I Pharmacokinetic Study of HUYPS-1 in Healthy Volunteers
Official title: A Randomized, Open-label, Single Dose, Crossover Design Phase I Study to Evaluate Tolerability, Safety and Pharmacokinetics of HUYPS-1 in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Nonalcoholic Steatohepatitis
Lead sponsor: Sinew Pharma Inc.
Sponsor class: INDUSTRY
First posted: 2023-08-09
Enrollment: 14
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Fasting Period: At least 10 hours prior to dosing until 4 hours post-dose of each study period.

Period: 24 hours post dose in each period. Each subject will complete two study periods.

Washout Period: At least one week after dosing of the previous period.

Confinement: From at least 10 hours prior to dosing until at least 12 hours post-dose, for a total of at least 22 hours for each study period.

Detailed description: This study is a single center and open-label design to evaluate tolerability, safety and pharmacokinetic properties of HUYPS-1 after single oral administration in healthy subjects under fasting conditions. A total of 14 eligible subjects are expected to be enrolled to ensure 12 evaluable subjects. The study will be completed when there are at least 12 evaluable subjects. The evaluable subjects are those who have completed both periods. Eligible subjects will be randomly assigned to either of the two treatment sequences.

The study design in a 2-sequence, 2-period crossover design. There is at least 7-day washout time between periods. The formulation of HUYPS-1 for oral administration contains 100 mg mannitol and 100 mg sucralose per tablet will be given by one or nine tablets per person of each period. Mannitol and sucralose are both commonly used excipients approved by WHO. These excipients are included in the FDA Inactive Ingredients Guide, GRAS (generally recognized as safe) and commonly used pharmaceutical excipients, therefore the oral doses of these excipients can be regarded as extremely safe in this study.

Eligibility criteria: Inclusion Criteria:

1. Normal healthy adult subjects between 20-50 years of age.
2. Acceptable medical history and physical examination including:
3. Acceptable clinical laboratory determinations without significant deviation from normal values within two months prior to Period I dosing, which includes AST (SGOT), ALT (SGPT), r-GT, alkaline phosphatase, total bilirubin, albumin, glucose, BUN, uric acid, creatinine, total cholesterol, triglyceride (TG) and galactose single point (GSP).
4. Acceptable hematology within two months prior to the study, which includes hemoglobin, hematocrit, red blood cells, MCV, MCH, MCHC, white blood cells, differential white blood cells and platelets.
5. Acceptable urinalysis within two months prior to the study, which includes pH, blood, glucose and protein.
6. Signed the written informed consent to participate in this study.
7. Acceptable body mass index (BMI): 18.5 \< BMI \< 25 kg/m2

Exclusion Criteria:

1. Recent history of drug or alcohol addiction or abuse within the past year.
2. A clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine or neurologic system(s) or psychiatric disease (as determined by the clinical investigator).
3. History of allergic response(s) to mannitol, sucralose or related drugs.
4. History of clinically significant allergies including drug allergies or allergic bronchial asthma.
5. Evidence of chronic or acute infectious diseases.
6. Any clinically significant illness or surgery during the one month prior to Period I dosing (as determined by the clinical investigator).
7. Taking any drug known to induce or inhibit hepatic drug metabolism within one month prior to the beginning of the study.
8. Receiving any investigational drug within one month prior to Period I dosing.
9. Taking any prescription medication or any nonprescription medication within two weeks prior to Period I doing.
10. Donating greater than 150 mL of blood within two months prior to Period I dosing or donating plasma (e.g. plasmapheresis) within two weeks prior to Period I dosing. All subjects will be advised not to donate blood for four weeks after completing the study.
11. Consumption of caffeine, xanthine-containing products (i.e. coffee, tea, caffeine-containing sodas, colas and chocolate, etc.) and/or alcohol, smoke or use tobacco products within 48 hours prior to days on which dosing is scheduled and during the periods when blood samples are being collected.
12. Any other medical reason as determined by the clinical investigator.
13. Subject is pregnant or breastfeeding.
14. Women of childbearing potential disagree to use an acceptable method of contraception (e.g., hormonal contraceptives, IUD, barrier device or abstinence) throughout the study.

Primary outcomes:
measure: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs):
timeFrame: 24 hours
Secondary outcomes:
measure: Pharmacokinetic profile of maximum concentration of HUYPS-1 (Cmax)
timeFrame: 24 hours
measure: Pharmacokinetic profile of time of occurrence for maximum (peak) HUYPS-1 concentration (Tmax)
timeFrame: 24 hours
measure: Pharmacokinetic profile of area under curve (AUC0-t) for HUYPS-1
timeFrame: 24 hours
measure: Pharmacokinetic profile of area under curve infinity (AUCINF) for HUYPS-1
timeFrame: 24 hours
measure: Pharmacokinetic profile of overall HUYPS-1 elimination rate constant (k)
timeFrame: 24 hours
measure: Pharmacokinetic profile of elimination half-life (T1/2) for HUYPS-1
timeFrame: 24 hours
measure: Pharmacokinetic profile of mean residence time (MRT) for HUYPS-1
timeFrame: 24 hours
measure: Pharmacokinetic profile of clearance (CL/F) for HUYPS-1
timeFrame: 24 hours
measure: Pharmacokinetic profile of apparent volume (Vd/F) for HUYPS-1
timeFrame: 24 hours
measure: Pharmacokinetic profile of area under moment curve (AUMC(0-t)) for HUYPS-1
timeFrame: 24 hours
measure: Pharmacokinetic profile of area under moment curve infinity (AUMCINF) for HUYPS-1
timeFrame: 24 hours
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Tri-Service General Hospital
Study officials:
References: